Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, wind and energy tax credits by 2028. Sarepta Therapeutics falls sharply ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory ...

The drugmaker is paying MeiraGTx $75 million upfront and $400 million in milestone payments to gain access to a treatment for LCA4 caused by AIPL1 mutations.

MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a death last month in a trial of an unrelated gene therapy.

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

Merck, the pharmaceutical giant with multiple locations across Montco, is reporting success with a new oral cholesterol drug, according to Reuters. The drug, enlicitide decanoate, recently met its ...

Fintel reports that on June 17, 2025, William Blair downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from Outperform to Market Perform. Analyst Price Forecast Suggests 125.57% Upside As ...